Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 26, 2007

Microtest to Manufacture First Anticancer Aptamer for Clinical Testing

  • Microtest signed a deal with Antisoma to immediately begin the aseptic manufacturing of AS1411, a drug being developed for the treatment of various cancers.

    “AS1411 is the first aptamer to be tested in cancer clinical trials. After successfully completing Phase I trials, we are now advancing to Phase II trials in renal cancer and AML,” says Glyn Edwards, Antisoma’s CEO.

    Microtest will be responsible for the formulation and aseptic fill/finish of AS1411 material supply for forthcoming Phase II trials. In addition, it will be responsible for stability testing of the AS1411 product.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »